Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinoma
PURPOSE - - Several anti-programmed cell death (ligand)-1 (PD-[L]1) immune checkpoint inhibitors are approved in advanced/metastatic urothelial carcinoma (mUC). Recently, improved activity of an anti-PD-1/anticytotoxic T-cell lymphocyte-4 (CTLA-4) combination versus anti-PD-1 monotherapy has been r...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 11, 2022
|
| In: |
Journal of clinical oncology
Year: 2022, Jahrgang: 40, Heft: 19, Pages: 2128-2137 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.21.02631 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.21.02631 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.21.02631 
|
| Verfasserangaben: | Marc-Oliver Grimm, Bernd Jürgen Schmitz-Dräger, Uwe Zimmermann, Christine Barbara Grün, Gustavo Bruno Baretton, Marc Schmitz, Susan Foller, Katharina Leucht, Martin Schostak, Friedemann Zengerling, Ulrike Schumacher, Wolfgang Loidl, and Johannes Meran |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1813097216 | ||
| 003 | DE-627 | ||
| 005 | 20230427070240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220803s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.21.02631 |2 doi | |
| 035 | |a (DE-627)1813097216 | ||
| 035 | |a (DE-599)KXP1813097216 | ||
| 035 | |a (OCoLC)1341464768 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Grimm, Marc-Oliver |d 1967- |e VerfasserIn |0 (DE-588)115682899 |0 (DE-627)077402952 |0 (DE-576)290017521 |4 aut | |
| 245 | 1 | 0 | |a Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinoma |c Marc-Oliver Grimm, Bernd Jürgen Schmitz-Dräger, Uwe Zimmermann, Christine Barbara Grün, Gustavo Bruno Baretton, Marc Schmitz, Susan Foller, Katharina Leucht, Martin Schostak, Friedemann Zengerling, Ulrike Schumacher, Wolfgang Loidl, and Johannes Meran |
| 264 | 1 | |c March 11, 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.08.2022 | ||
| 520 | |a PURPOSE - - Several anti-programmed cell death (ligand)-1 (PD-[L]1) immune checkpoint inhibitors are approved in advanced/metastatic urothelial carcinoma (mUC). Recently, improved activity of an anti-PD-1/anticytotoxic T-cell lymphocyte-4 (CTLA-4) combination versus anti-PD-1 monotherapy has been reported. We report a response-based approach starting treatment with nivolumab monotherapy with nivolumab/ipilimumab as immunotherapeutic boost. - - METHODS - - After four doses of nivolumab induction, responders continued with nivolumab maintenance therapy. Patients with stable/progressive disease received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg once every 3 weeks for 2 doses followed by nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for 2 doses, if not responding to the initial boost. Responders to boosts continued with nivolumab maintenance. Between July 2017 and April 2019, 86 patients were enrolled. The median follow-up is 7.7 months. The primary end point is objective response rate (ORR) per RECIST1.1. Secondary end points include efficacy of nivolumab induction, remission rate with nivolumab/ipilimumab boosts, overall survival, and safety. - - RESULTS - - Of all patients, 42, 39, and five were first- (1L), second- (2L), and third-line (3L), respectively. The median age was 68 years. The ORR with nivolumab monotherapy (assessed at week 8) was 29% in 1L and 23% in 2/3L, respectively. Forty-one patients received early (week 8) and 11 received later nivolumab/ipilimumab boosts. ORRs with nivolumab with or without nivolumab/ipilimumab (best overall response) were 45% and 27% in 1L and 2/3L, respectively. In 1L, 7 of 17 patients receiving boosts at week 8 improved, compared with 2 of 24 in 2/3L. - - CONCLUSION - - The tailored approach of TITAN-TCC shows meaningful clinical activity supporting dual checkpoint inhibition in 1L mUC. However, starting therapy with nivolumab exclusively appears inadequate given the aggressive nature of mUC. In 2/3L, nivolumab/ipilimumab boosts with escalating ipilimumab dose did not improve efficacy outcomes versus nivolumab monotherapy. An independent 2L cohort of TITAN-TCC receiving nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for 4 doses is ongoing. | ||
| 700 | 1 | |a Schmitz-Dräger, Bernd Jürgen |e VerfasserIn |0 (DE-588)1068899832 |0 (DE-627)821001728 |0 (DE-576)42827241X |4 aut | |
| 700 | 1 | |a Zimmermann, Uwe |d 1961- |e VerfasserIn |0 (DE-588)118120042 |0 (DE-627)694686379 |0 (DE-576)291725597 |4 aut | |
| 700 | 1 | |a Grün, Barbara |e VerfasserIn |0 (DE-588)1161226311 |0 (DE-627)1024632121 |0 (DE-576)506420922 |4 aut | |
| 700 | 1 | |a Baretton, Gustavo Bruno |e VerfasserIn |0 (DE-588)1022411691 |0 (DE-627)716964848 |0 (DE-576)365286346 |4 aut | |
| 700 | 1 | |a Schmitz, Marc |d 1968- |e VerfasserIn |0 (DE-588)115796622 |0 (DE-627)077478932 |0 (DE-576)18742523X |4 aut | |
| 700 | 1 | |a Foller, Susan |e VerfasserIn |0 (DE-588)1270828711 |0 (DE-627)1819620662 |4 aut | |
| 700 | 1 | |a Leucht, Katharina |d 1983- |e VerfasserIn |0 (DE-588)1187839175 |0 (DE-627)1666809349 |4 aut | |
| 700 | 1 | |a Schostak, Martin |d 1965- |e VerfasserIn |0 (DE-588)1079258043 |0 (DE-627)840728409 |0 (DE-576)452316707 |4 aut | |
| 700 | 1 | |a Zengerling, Friedemann H. |d 1982- |e VerfasserIn |0 (DE-588)141455977 |0 (DE-627)629424144 |0 (DE-576)324220278 |4 aut | |
| 700 | 1 | |a Schumacher, Ulrike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loidl, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meran, Johannes |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 40(2022), 19, Seite 2128-2137 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinoma |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:19 |g pages:2128-2137 |g extent:10 |a Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinoma |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.21.02631 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.21.02631 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220803 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1161226311 |a Grün, Barbara |m 1161226311:Grün, Barbara |d 910000 |d 910100 |d 50000 |e 910000PG1161226311 |e 910100PG1161226311 |e 50000PG1161226311 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1813097216 |e 4175587535 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinoma","title_sort":"Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinoma"}],"person":[{"family":"Grimm","given":"Marc-Oliver","role":"aut","display":"Grimm, Marc-Oliver"},{"role":"aut","given":"Bernd Jürgen","family":"Schmitz-Dräger","display":"Schmitz-Dräger, Bernd Jürgen"},{"display":"Zimmermann, Uwe","given":"Uwe","role":"aut","family":"Zimmermann"},{"given":"Barbara","role":"aut","family":"Grün","display":"Grün, Barbara"},{"display":"Baretton, Gustavo Bruno","given":"Gustavo Bruno","role":"aut","family":"Baretton"},{"display":"Schmitz, Marc","family":"Schmitz","given":"Marc","role":"aut"},{"given":"Susan","role":"aut","family":"Foller","display":"Foller, Susan"},{"display":"Leucht, Katharina","family":"Leucht","given":"Katharina","role":"aut"},{"family":"Schostak","role":"aut","given":"Martin","display":"Schostak, Martin"},{"family":"Zengerling","role":"aut","given":"Friedemann H.","display":"Zengerling, Friedemann H."},{"display":"Schumacher, Ulrike","given":"Ulrike","role":"aut","family":"Schumacher"},{"role":"aut","given":"Wolfgang","family":"Loidl","display":"Loidl, Wolfgang"},{"display":"Meran, Johannes","given":"Johannes","role":"aut","family":"Meran"}],"language":["eng"],"physDesc":[{"extent":"10 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"March 11, 2022","dateIssuedKey":"2022"}],"id":{"eki":["1813097216"],"doi":["10.1200/JCO.21.02631"]},"recId":"1813097216","name":{"displayForm":["Marc-Oliver Grimm, Bernd Jürgen Schmitz-Dräger, Uwe Zimmermann, Christine Barbara Grün, Gustavo Bruno Baretton, Marc Schmitz, Susan Foller, Katharina Leucht, Martin Schostak, Friedemann Zengerling, Ulrike Schumacher, Wolfgang Loidl, and Johannes Meran"]},"note":["Gesehen am 03.08.2022"],"relHost":[{"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}],"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2005181-5"],"issn":["1527-7755"],"eki":["313116962"]},"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-"}],"recId":"313116962","disp":"Tailored immunotherapy approach with Nivolumab in advanced transitional cell carcinomaJournal of clinical oncology","titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"pubHistory":["1.1983 -"],"part":{"extent":"10","text":"40(2022), 19, Seite 2128-2137","pages":"2128-2137","volume":"40","year":"2022","issue":"19"}}]} | ||
| SRT | |a GRIMMMARCOTAILOREDIM1120 | ||